MedAvail Holdings, Inc.

Report azionario NasdaqCM:MDVL

Capitalizzazione di mercato: US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MedAvail Holdings Gestione

Criteri Gestione verificati 1/4

MedAvail Holdings Il CEO è Mark Doerr, nominato in Jan2022, e ha un mandato di 2.08 anni. la retribuzione annua totale è $ 2.52M, composta da 16.8% di stipendio e 83.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.23% delle azioni della società, per un valore di $ 6.79K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 2.7 anni.

Informazioni chiave

Mark Doerr

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO16.80%
Mandato del CEO2.1yrs
Proprietà del CEO0.2%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Aug 17

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

MedAvail Holdings, Inc. ( NASDAQ:MDVL ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Aug 02

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail is a prescription drug-dispensing kiosks startup whose revenues are growing by over 100% year-on-year at the moment. However, the gross margin is barely positive and the operating loss expanded to $12.8 million in Q1 2022. Cash used in operational activities rose to $13.3 million in Q1 2022 and I think that the company will need another capital increase around the end of the year. However, short selling seems dangerous at the moment as the short borrow fee rate is almost 80%. Introduction I like writing about under covered stocks on SA, and today I'm taking a look at MedAvail Holdings (MDVL). It's a company focused on pharmacy automation kiosks and the growth of its business looks compelling. However, the operating expenses are high and the company is set to run low on cash again soon. I think that another stock dilution seems inevitable in the near future. Overall, I don't think that the business is worth much in its current state and I'm bearish. Let's review. Overview of the business and financials MedAvail is a pharmacy technology and services company whose main product is a MedCenter. This is a pharmacist controlled, customer-interactive, prescription dispensing system that looks somewhat like an ATM on the outside. MedAvail It's an interesting concept but there are several competitors with a similar business, including Omnicell (NASDAQ: OMCL) Dispension Industries, Pharmaself24. What MedAvail is offering doesn't seem to be unique. The company also operates full-service retail pharmacies under the SpotRx brand that use its automated pharmacy technology. MedAvail has bet on a hub and spoke model and it currently has operations in the states of Arizona, California, Michigan, and Florida. It plans to set foot in Texas and Illinois in the near future. MedAvail has partnered with several large brands, including IMA Medical Group, CareMore Health, Cigna (NYSE: CI), and Cano Health. MedAvail The dispensing units usually ramp up to $1 million in annual revenues by their second year. As of December 2021, MedAvail had a total of 13 dispensing units that were operating for over 18 months, and it plans to set up about 25-30 dispensing units in 2022. For the graphs below, note that net cumulative deployments exclude decommissioned clinics, pilot and demo sites. MedAvail MedAvail In Q1 2022, retail pharmacy and hardware revenues increased by 126.3% year-on-year thanks to a $5.4 million increase from volume growth in prescription revenue at existing sites as well as new sites in Florida and Michigan. Unfortunately, there don't appear to be significant economies of scale as the total cost of products sold and services soared by 132.3% to $8.61 million. In addition, operating expenses rose by 33.1% which led to a widening of the operating loss of MedAvail to $12.8 million in Q1 2022. MedAvail Looking at the future, the targeted milestones listed in MedAvail's latest corporate presentation include increasing the network of dispensing MedCenters to more than 100 in existing markets. I don't think this should be hard to achieve considering there were already 88 dispensing units in operation as of March 2022, up from 68 units in December 2021. The company also aims to reduce its quarterly cash burn by 20% by improving its gross margin and achieving greater hub pharmacy utilization. It also highlighted a procurement strategy for sourcing pharmaceuticals at optimal cost to drive utilization and the appropriate mix of medications. However, I don't see a path to profitability anytime soon considering the gross margin hasn't seen much improvement over the past few quarters and that the operating loss has increased by over 37% in just a year. In my view, this is a major issue as it has led to an increase of net cash used in operating activities to $13.3 million in Q1 2022, compared to $9.8 million a year earlier. As a result, MedAvail closed March with cash and cash equivalents of only $5.27 million. The company then raised $40 million through the issuance of 37.6 million shares at $1.0625 apiece in April 2022. Yet, I think that another large private placement is likely to take place around the end of 2022 due to the increase of cash used in operating activities. I think that more stock dilution seems inevitable at the moment. Turning our attention to the balance sheet, we can see that MedAvail has an asset-light business model and cash, receivables, and inventories accounted for almost half of the $27.7 million in total assets at the end of Q1 2022. I find it concerning that the accumulated deficit has surpassed $200 million. MedAvail Overall, I expect MedAvail to continue growing its revenues at a rapid pace and I think the annual run rate could surpass $50 million by the end of 2022. However, the gross margin is barely positive and when you add operating expenses, the picture isn't pretty. And with net cash used in operations growing rapidly, I think that another large capital increase is likely in a few months. I'm bearish but I don't think that this is a good time to be short selling MedAvail. According to data from Fintel, there are 250,000 shares available for borrowing as of the time of writing but the short borrow fee rate is 79.39%. And if you want to rely on put options instead, the lowest available strike price at the moment is $2.50.
Articolo di analisi • Aug 17

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

The latest analyst coverage could presage a bad day for MedAvail Holdings, Inc ( NASDAQ:MDVL ), with the analysts...
Articolo di analisi • May 24

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

Does the May share price for MedAvail Holdings, Inc ( NASDAQ:MDVL ) reflect what it's really worth? Today, we will...
Articolo di analisi • Feb 20

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

In this article we are going to estimate the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mark Doerr rispetto agli utili di MedAvail Holdings?
DataCompenso totaleStipendioUtili della società
Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$55m

Dec 31 2022US$3mUS$424k

-US$48m

Compensazione vs Mercato: La retribuzione totale di Mark ($USD 2.52M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 629.02K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Mark con le performance aziendali.

AMMINISTRATORE DELEGATO

Mark Doerr (53 yo)

2.1yrs
Mandato
US$2,524,419
Compensazione

Mr. Mark Doerr, RPh serves as Chief Executive Officer, President and Director at MedAvail Holdings, Inc since January 10, 2022. He serves as the Chief Executive Officer of eRx Network, LLC since March 28,...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Ramona Seabaugh
CFO, Treasurer & Secretary2.4yrsUS$537.22k0.076%
$ 2.2k
Emilia Keric
Senior VP & General Counselless than a yearNessun datoNessun dato
Joan O'Rourke
President of SpotRx2.8yrsNessun datoNessun dato
Brian Schlerf
Corporate Controller3.1yrsNessun datoNessun dato
2.4yrs
Durata media

Gestione esperta: Il team dirigenziale di MDVL è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Robert Faulkner
Chairman of the Board3.3yrsNessun dato0.12%
$ 3.6k
Laurie McGraw
Independent Director2.1yrsUS$217.96k0%
$ 0
Michael Kramer
Independent Director3.3yrsUS$187.00k0%
$ 0
Glen Stettin
Independent Director3.3yrsUS$170.00k0%
$ 0
Paul Johnson
Independent Director2.1yrsUS$224.96k0%
$ 0
2.7yrs
Durata media
56yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MDVL non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/02/03 16:51
Prezzo dell'azione a fine giornata2024/02/02 00:00
Utili2023/06/30
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

MedAvail Holdings, Inc. è coperta da 2 analisti. di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Brooks O'NeilLake Street Capital Markets, LLC
Charles RhyeeTD Cowen